Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 693 results found. Search for [ Cipla ]

Results 1 to 21 of 693
E Kumar Sharma
New Delhi, September 13, 2018
As the industry is trying to digest the development, not totally unexpected though, there are fresh concerns on what could come next as the ministry-appointed Prof Kokate Expert committee had discussed banning many more FDC drugs.


BusinessToday.In
New Delhi, September 13, 2018
India reportedly boasts around 2,000 FDCs, four times more that what's available in the US.


E Kumar Sharma
New Delhi, September 6, 2018
Experts, who have studied family-led businesses, offer some lessons.


Rajeev Dubey
New Delhi, September 3, 2018
Prathiba singh has contributed to some of the most important IPR laws and given landmark judgments.


BusinessToday.In
August 28, 2018
At 9:36 am, the Sensex was trading 114 points higher at 38808 level. The Nifty gained 26 points to 11,718 level. NTPC (2.77%), Coal India (1.56%) and Vedanta (1.06%) were the top Sensex gainers.


BusinessToday.In
August 9, 2018
At 9:56 am, the Sensex was trading 117 points higher at 38,004 level.  Meanwhile, the Nifty inched closer to the 11,500 level,  rising 45 points from its previous close. It hit all time high of 11,495 level.


E Kumar Sharma
New Delhi, July 18, 2018
Those within the pharma industry see a couple of messages coming across from the movie.


E. Kumar Sharma
New Delhi, June 25, 2018
Y.C. Deveshwar at ITC and A.M. Naik at L&T have built a legacy any corporate leader would be proud of. Then there are others whose initiatives are still in the process of bearing fruit.


BusinessToday.In
New Delhi, June 17, 2018
Rahul Agarwal, Director, Wealth Discovery, talks about the ups and downs of equity share market in the BusinessToday.In video.


PTI
June 8, 2018



PTI
June 8, 2018



E Kumar Sharma
New Delhi, June 8, 2018
The Indian pharma has recently seen a perceptible slide in the number of new products hitting the market. According to the analysts, slippages are more in select therapies and they attribute this to several reasons.


E Kumar Sharma
May 24, 2018
Analysts read several things into it. First, they linked it to the fact that there was no negative shock especially in the US part of the business. There was a negative in the performance in Russia, an important contributor to the profitability of the company.


PTI
May 22, 2018



PTI
May 22, 2018



PTI
May 20, 2018



PTI
May 18, 2018



PTI
May 18, 2018



PTI
May 16, 2018



P.B. Jayakumar
New Delhi, April 30, 2018
Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities.


PAGES 1 OF 35  12345